[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574702":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":18,"locations":24,"responsibleParty":41,"collaborators":7,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":7,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":7,"enrollmentInfo":52,"targetDuration":7,"studyType":55,"phases":7,"briefSummary":56,"conditions":57,"keywords":7,"overallStatus":27,"whyStopped":7,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"Boston Scientific Corporation","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DEVICE","FARAPULSE™ Pulsed Field Ablation system","no intervention design in the study",[14],{"name":15,"affiliation":16,"role":17},"Min Tang, Dr","Chinese Academy of Medical Sciences, Fuwai Hospital","PRINCIPAL_INVESTIGATOR",[19],{"name":20,"role":21,"phone":22,"phoneExt":7,"email":23},"Hui Lin","CONTACT","15810430945","Hui.Lin@bsci.com",[25],{"facility":26,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Fuwai Hospital, Chinese Academy of Medical Sciences","RECRUITING","Beijing","China\u002FBeijing","100037","China","CN",{"type":34,"coordinates":35},"Point",[36,37],116.39723,39.9075,{"lat":37,"lon":36},[40],{"name":15,"role":21,"phone":7,"phoneExt":7,"email":7},{"type":42,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100574702","farapulse-pulsed-field-ablation-system-100574702",false,"NCT06762717","FARAPULSE™ Pulsed Field Ablation System","Real World Data Collection in Chinese Population Treated With the FARAPULSE™ Pulsed Field Ablation System","Inclusion Criteria:\n\n1. Subjects intended to be treated with the FARAPULSE™ Pulsed Field Ablation system for cardiac tissue ablation, per physician's medical judgement, and as per hospitals' standard of care\n2. Subjects who are willing and capable of providing informed consent\n3. Subjects who are willing and capable of participating in all testing associated with this clinical study at an approved clinical investigational center\n4. Subjects whose age is 18 years or above.\n\nExclusion Criteria:\n\n1. Subjects with a current interatrial baffle or patch\n2. Subjects with a known or suspected atrial myxoma\n3. Subjects with a myocardial infarction within 14 days prior to enrollment\n4. Subjects with a recent (within 30 days prior to enrollment) Cerebral Vascular Accident (CVA)\n5. Subjects who do not tolerate anticoagulation therapy\n6. Subjects with an active systemic infection \\*\n7. Subjects with a presence of atrial known thrombus \\*\n8. Subjects with a known inability to obtain vascular access\n9. Subjects who are pregnant or planning to be pregnant\n10. Subjects with atrial fibrillation that is secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible \u002F non-cardiac causes\n11. Subjects with any prosthetic heart valve, ring or repair including balloon aortic valvuloplasty\n12. Subjects with a contraindication to an invasive electrophysiology procedure where insertion or manipulation of a catheter in the cardiac chambers is deemed unsafe per physician's medical judgement, such as, but not limited to, a recent previous cardiac surgery (e.g., ventriculotomy or atriotomy, CABG, PTCA\u002FPCI\u002Fcoronary stent procedure), recent previous unstable angina and\u002For in patients with congenital heart disease where the underlying abnormality increases the risk of the ablation (e.g., severe rotational anomalies of the heart or great vessels)\n13. Subjects with a life expectancy of ≤ 1 year per investigator's opinion\n14. Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments. Each instance must be brought to the attention of the sponsor to determine eligibility.","ALL","18 Years",{"count":53,"type":54},500,"ESTIMATED","OBSERVATIONAL","To obtain real world data on the use of, and provide continued evidence on safety and effectiveness of the FARAPULSE™ Pulsed Field Ablation (PFA) system when used per hospitals' standard of care in Chinese population.",[58],"Paroxysmal AF","2026-06-28",{"date":61,"type":62},"2026-06-30","ACTUAL",{"date":64,"type":62},"2025-10-23",{"date":66,"type":54},"2029-12-31",{"name":5,"class":6},1]